Online inquiry

IVTScrip™ mRNA-Anti-VEGFA, AT-001(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3329MR)

This product GTTS-WQ3329MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets VEGFA gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001025366.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7422
UniProt ID P15692
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-VEGFA, AT-001(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ3329MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ12335MR IVTScrip™ mRNA-Anti-TIGIT, MTIG-7192-A(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MTIG-7192-A
GTTS-WQ6360MR IVTScrip™ mRNA-Anti-MSTN, CSL-362-AML(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CSL-362-AML
GTTS-WQ11022MR IVTScrip™ mRNA-Anti-CD3E&CLEC12A, MCLA-117(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA MCLA-117
GTTS-WQ9440MR IVTScrip™ mRNA-Anti-KLRC1, IPH-2201(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA IPH-2201
GTTS-WQ4430MR IVTScrip™ mRNA-Anti-CTLA4, BMS-734016(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-734016
GTTS-WQ12428MR IVTScrip™ mRNA-Anti-IFNG, NI-0501(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA NI-0501
GTTS-WQ12769MR IVTScrip™ mRNA-Anti-NOTCH1, OMP-52M51(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA OMP-52M51
GTTS-WQ15611MR IVTScrip™ mRNA-Anti-TNFRSF13C, VAY-736(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA VAY-736
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW